What is Aknefug Mino?
Aknefug Mino is used to treat pimples and red bumps (non-nodular inflammatory lesions) that occur with moderate to severe acne vulgaris in patients 12 years of age and older.
Aknefug Mino capsules are used to treat bacterial infections in many different parts of the body. It is also used to treat anthrax infection and other infections in patients who cannot receive penicillins.
Aknefug Mino belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth. However, Aknefug Mino will not work for colds, flu, or other virus infections.
Aknefug Mino is available only with your doctor's prescription.
Aknefug Mino indications
Aknefug Mino® Pellet-Filled Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms:
Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae.
Respiratory tract infections caused by Mycoplasma pneumoniae.
Lymphogranuloma venereum caused by Chlamydia trachomatis.
Psittacosis (Ornithosis) due to Chlamydia psittaci.
Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence.
Inclusion conjunctivitis caused by Chlamydia trachomatis.
Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis.
Relapsing fever due to Borrelia recurrentis.
Chancroid caused by Haemophilus ducreyi.
Plague due to Yersinia pestis.
Tularemia due to Francisella tularensis.
Cholera caused by Vibrio cholerae.
Campylobacter fetus infections caused by Campylobacter fetus.
Brucellosis due to Brucella species (in conjunction with streptomycin).
Bartonellosis due to Bartonella bacilliformis.
Granuloma inguinale caused by Calymmatobacterium granulomatis.
Aknefug Mino is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:
Escherichia coli.
Enterobacter aerogenes.
Shigella species.
Acinetobacter species.
Respiratory tract infections caused by Haemophilus influenzae.
Respiratory tract and urinary tract infections caused by Klebsiella species.
Aknefug Mino® Pellet-Filled Capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:
Upper respiratory tract infections caused by Streptococcus pneumoniae.
Skin and skin structure infections caused by Staphylococcus aureus. (Note: Aknefug Mino is not the drug of choice in the treatment of any type of staphylococcal infection.)
When penicillin is contraindicated, Aknefug Mino is an alternative drug in the treatment of the following infections:
Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections.
Infections in women caused by Neisseria gonorrhoeae.
Syphilis caused by Treponema pallidum subspecies pallidum.
Yaws caused by Treponema pallidum subspecies pertenue.
Listeriosis due to Listeria monocytogenes.
Anthrax due to Bacillus anthracis.
Vincent’s infection caused by Fusobacterium fusiforme.
Actinomycosis caused by Actinomyces israelii.
Infections caused by Clostridium species.
In acute intestinal amebiasis, Aknefug Mino may be a useful adjunct to amebicides.
In severe acne, Aknefug Mino may be useful adjunctive therapy.
Oral Aknefug Mino is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of Aknefug Mino in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of Aknefug Mino be reserved for situations in which the risk of meningococcal meningitis is high.
Oral Aknefug Mino is not indicated for the treatment of meningococcal infection.
Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral Aknefug Mino has been used successfully in the treatment of infections caused by Mycobacterium marinum.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Aknefug Mino® (Aknefug Mino) Pellet-Filled Capsules and other antibacterial drugs, Aknefug Mino® (Aknefug Mino) Pellet-Filled Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How should I use Aknefug Mino?
Use Aknefug Mino extended-release tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Aknefug Mino extended-release tablets. Talk to your pharmacist if you have questions about this information.
- Take Aknefug Mino extended-release tablets by mouth with or without food. Taking Aknefug Mino extended-release tablets with food or milk may decrease stomach upset. However, certain foods and milk may bind with Aknefug Mino extended-release tablets, preventing its full absorption. Discuss any questions or concerns with your doctor.
- Swallow Aknefug Mino extended-release tablets whole. Do not break, crush, or chew before swallowing.
- Take Aknefug Mino extended-release tablets with a full glass of water (8 oz [240 mL]). Do not lie down for 30 minutes after taking Aknefug Mino extended-release tablets.
- Do not take medicines that have aluminum, magnesium, calcium, or zinc (eg, multivitamins, antacids, quinapril), bismuth, or urinary alkalinizers (eg, sodium bicarbonate) in them within 2 hours before or after you take Aknefug Mino extended-release tablets.
- Do not take medicines that have iron (eg, ferrous sulfate) in them within 3 hours before or 2 hours after taking Aknefug Mino extended-release tablets. If you need to take iron, check with your doctor about the right type of iron to take along with Aknefug Mino extended-release tablets.
- Aknefug Mino extended-release tablets works best if it is taken at the same time each day.
- Do not miss any doses. If you miss a dose of Aknefug Mino extended-release tablets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Aknefug Mino extended-release tablets.
Uses of Aknefug Mino in details
Use: Labeled Indications
Acute intestinal amebiasis: Adjunctive therapy to amebicides in the treatment of acute intestinal amebiasis
Acne:
Oral (immediate release) and IV:
Adjunctive therapy for the treatment of severe acne
Oral (extended-release):
Treatment of only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years and older
Actinomycosis: Treatment of actinomycosis caused by Actinomyces israelii when penicillin is contraindicated
Anthrax: Treatment of anthrax caused by Bacillus anthracis when penicillin is contraindicated
Asymptomatic carriers of Neisseria meningitidis: Oral (immediate-release):
To eliminate the meningococci from the nasopharynx of asymptomatic carriers of N. meningitidis
Campylobacter: Treatment of infections caused by Campylobacter fetus
Cholera: Treatment of cholera caused by Vibrio cholerae
Clostridium: Treatment of infections caused by Clostridium spp when penicillin is contraindicated
Gram-negative infections: Treatment of infections caused by Acinetobacter spp, Escherichia coli, Enterobacter aerogenes, Shigella spp
Listeriosis: Treatment of listeriosis due to Listeria monocytogenes when penicillin is contraindicated
Meningitis: Treatment of meningitis due to Neisseria meningitidis when penicillin is contraindicated
Ophthalmic infections:
Treatment of inclusion conjunctivitis or trachoma caused by Chlamydia trachomatis
Relapsing fever: Treatment of relapsing fever caused by Borrelia recurrentis
Respiratory tract infections: Treatment of respiratory tract infections caused by Haemophilus influenzae, Klebsiella spp, or Mycoplasma pneumonia. For the treatment of upper respiratory tract infections caused by Streptococcus pneumoniae.
Rickettsial infections: Treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae
Sexually transmitted infections: Treatment of lymphogranuloma venereum caused by C. trachomatis; nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or C. trachomatis; donovanosis (granuloma inguinale) caused by Klebsiella granulomatis; syphilis caused by Treponema pallidum subspecies pallidum, when penicillin is contraindicated
Skin and skin structure infections: Treatment of skin and skin structure infections caused by Staphylococcus aureus (not considered a first-line agent for any staphylococcal infection)
Urinary tract infections: Treatment of urinary tract infections caused by Klebsiella species
Vincent infection: Treatment of Vincent infection caused by Fusobacterium fusiforme when penicillin is contraindicated
Yaws: Treatment of yaws caused by T. pallidum subspecies pertenue when penicillin is contraindicated
Zoonotic infections: Treatment of psittacosis (ornithosis) due to Chlamydia psittaci; plague due to Yersinia pestis; tularemia due to Francisella tularensis; brucellosis due to Brucella spp (in conjunction with streptomycin); bartonellosis due to Bartonella bacilliformis
Off Label Uses
Cellulitis (purulent) due to community-acquired MRSA
Based on the Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children, Aknefug Mino is effective and recommended in the outpatient management of purulent cellulitis due to community-acquired methicillin-resistant S. aureus (MRSA).
Leprosy
Based on the National Hansen's Disease Program (NHDP) treatment recommendations, Aknefug Mino, in combination with other agents, is an effective and recommended alternative agent for treatment of lepromatous (multibacillary) and tuberculoid (paucibacillary) leprosy.
Nocardiosis
Data from a limited number of patients studied suggest that Aknefug Mino, with or without other concomitant antimicrobials, may be beneficial for the treatment of nocardiosis
Prosthetic Joint Infection
Based on the Infectious Diseases Society of America (IDSA) Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline, Aknefug Mino (based on in vitro susceptibility) given for indefinite chronic oral antimicrobial suppression of prosthetic joint infections is an effective and recommended treatment option. Aknefug Mino is one of the preferred agents for Staphylococci (oxacillin-resistant) infections and is an alternative treatment for infections caused by Cutibacterium spp.
Rheumatoid arthritis
Data from older controlled studies and a meta-analysis have demonstrated a beneficial effect on laboratory parameters and modest clinical benefit in patients with rheumatoid arthritis (RA). Some data suggest that Aknefug Mino may be effective in patients with recent-onset disease to reduce the total steroid dose needed.
The American College of Rheumatology (ACR) updated guideline for the treatment of RA did not include Aknefug Mino due to its infrequent use in RA and lack of new data since prior publication.
Aknefug Mino description
Aknefug Mino is a yellow, crystalline powder; sparingly soluble or soluble in water, slightly soluble in alcohol, practically insoluble in chloroform and in ether, dissolves in solutions of alkali hydroxides and carbonates.
Aknefug Mino is 4-7, bis (dimethylamino)-1, 4, 4a, 5, 5a, 6, 11, 12a-octahydro-3,10,12, 12a-tetrahydroxy- 1,11-dioxo-2-naphthacenecarboxamide monohydrochloride.
It has a molecular formula of C23H27N3O7 HCl. Molecular weight is 493.94.
Aknefug Mino dosage
Aknefug Mino Dosage
Generic name: Aknefug Mino 45mg
Dosage form: tablet, film coated, extended release
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
The recommended dosage of Aknefug Mino® is approximately 1 mg/kg daily for 12 weeks. Higher doses have not shown to be of additional benefit in the treatment of inflammatory lesions of acne, and may be associated with more acute vestibular side effects.
The following table shows tablet strength and body weight to achieve approximately 1 mg/kg.
| Patient's Weight (lbs.) | Patient's Weight (kg) | Tablet Strength (mg) | Actual mg/kg Dose |
|---|---|---|---|
| 99 – 120 | 45 – 54 | 45 | 1 – 0.83 |
| 121 – 170 | 55 – 77 | 65 | 1.18 – 0.84 |
| 171 – 225 | 78 – 102 | 90 | 1.15 – 0.88 |
| 226 – 276 | 103 – 125 | 115 | 1.12 – 0.92 |
| 277 – 300 | 126 – 136 | 135 | 1.07 – 0.99 |
Aknefug Mino® Tablets may be taken with or without food. Ingestion of food along with Aknefug Mino® may help reduce the risk of esophageal irritation and ulceration.
In patients with renal impairment, the total dosage should be decreased by either reducing the recommended individual doses and/or by extending the time intervals between doses.
More about Aknefug Mino (Aknefug Mino)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 80 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Aknefug Mino
- Aknefug Mino extended-release tablets
- Aknefug Mino (Advanced Reading)
- Other brands: Aknefug Mino, Dynacin, Myrac, Ximino, More (1) »
Professional resources
- Aknefug Mino (FDA)
- Aknefug Mino eent (AHFS Monograph)
Related treatment guides
- Acne
- Rosacea
Aknefug Mino interactions
See also:
What other drugs will affect Aknefug Mino?
Anticoagulants
Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
Penicillin
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin.
Methoxyflurane
The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.
Antacids and Iron Preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations.
Low Dose
Oral Contraceptives
In a multi-center study to evaluate the effect of Aknefug Mino on low dose oral contraceptives, hormone levels over one menstrual cycle with and without Aknefug Mino 1 mg/kg once-daily were measured. Based on the results of this trial, Aknefug Mino-related changes in estradiol, progestinic hormone, FSH and LH plasma levels, of breakthrough bleeding, or of contraceptive failure, cannot be ruled out. To avoid contraceptive failure, female patients are advised to use a second form of contraceptive during treatment with Aknefug Mino.
Drug/Laboratory Test Interactions
False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.
Aknefug Mino side effects
See also:
What are the possible side effects of Aknefug Mino?
Applies to Aknefug Mino: oral capsule, oral capsule extended release, oral suspension, oral tablet, oral tablet extended release
Other dosage forms:
- intravenous powder for solution
As well as its needed effects, Aknefug Mino (the active ingredient contained in Aknefug Mino) may cause unwanted side effects that require medical attention.
Major Side Effects
If any of the following side effects occur while taking Aknefug Mino, check with your doctor immediately:
Incidence not known:
- Black, tarry stools
- blistering, peeling, or loosening of the skin
- blood in the urine or stools
- blurred or double vision
- bulging soft spot on the head of an infant
- chest pain, possibly moving to the left arm, neck, or shoulder
- confusion
- diarrhea
- dizziness or lightheadedness
- eye pain
- fast heartbeat
- general feeling of discomfort or illness
- general tiredness and weakness
- hives, itching, or skin rash
- joint or muscle pain
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- loss of appetite
- nausea or vomiting
- red skin lesions, often with a purple center
- severe headache
- severe stomach pain
- sores, ulcers, or white spots on the lips or in the mouth
- troubled breathing
- unusual bleeding or bruising
- upper right abdominal or stomach pain
- yellow eyes and skin
Minor Side Effects
Some Aknefug Mino side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:
Less common:
- Continuing ringing or buzzing or other unexplained noise in the ears
- difficulty with moving
- hearing loss
- hives or welts
- muscle stiffness
- redness of the skin
- sleepiness or unusual drowsiness
- Bloating
- discoloration of the tooth
- increased sensitivity of the skin to sunlight
- indigestion
- severe sunburn
Aknefug Mino contraindications
See also:
What is the most important information I should know about Aknefug Mino?
Do not use this medicine if you are pregnant. It could harm the unborn baby or cause permanent tooth discoloration later in life.
Aknefug Mino can make birth control pills less effective. Ask your doctor about using a non hormone method of birth control (such as a condom, diaphragm, spermicide) to prevent pregnancy while using Aknefug Mino.
Aknefug Mino passes into breast milk and may affect bone and tooth development in a nursing baby. Do not take this medication without telling your doctor if you are breast-feeding a baby.
Children should not take Aknefug Mino. Aknefug Mino can cause permanent yellowing or graying of the teeth in children younger than 8 years old.
Avoid exposure to sunlight or tanning beds. Aknefug Mino can make you sunburn more easily. Wear protective clothing and use sunscreen (SPF 30 or higher) when you are outdoors.
Do not take iron supplements, multivitamins, calcium supplements, antacids, or laxatives within 2 hours before or after taking Aknefug Mino. These products can make Aknefug Mino less effective.
Take this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics.
Throw away any unused medicine after the expiration date on the label has passed. Using expired Aknefug Mino can cause damage to your kidneys.
Active ingredient matches for Aknefug Mino:
Minocycline in Germany.
Minocycline hydrochloride in Germany.
List of Aknefug Mino substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Akne-Puren (Germany) | |
| Capsules; Oral; Minocycline Hydrochloride (Alpharma-isis) | |
| Aknemin (United Kingdom) | |
| Aknemin 100 (United Kingdom) | |
| Aknemin 50 (United Kingdom) | |
| Aknereduct (Germany) | |
| Aknin-Mino (Germany) | |
| Aknin-N (Switzerland) | |
| Capsule; Oral; Minocycline Hydrochloride 50 mg (Sanofi) | |
| Capsules; Oral; Minocycline Hydrochloride 50 mg (Sanofi) | |
| Aknoral (Switzerland) | |
| Capsule; Oral; Minocycline Hydrochloride 50 mg (Ibsa) | |
| Capsules; Oral; Minocycline Hydrochloride 50 mg (Ibsa) | |
| Aknosan (Germany) | |
| Tablet, Film-Coated; Oral; Minocycline Hydrochloride (Hermal) | |
| Tablets, Film-Coated; Oral; Minocycline Hydrochloride (Hermal) | |
| Alti-Minocycline | |
| Antinocil (Mexico) | |
| Apo-Minocycline (Canada, Hong Kong, Malaysia, Singapore) | |
| Capsule; Oral; Minocycline Hydrochloride 100 mg (Apotex) | |
| Capsule; Oral; Minocycline Hydrochloride 50 mg (Apotex) | |
| Apo-Minocycline 50 mg x 100's (Apotex) | |
| Apo-Minocycline 100 mg x 100's (Apotex) | |
| Capsules; Oral; Minocycline Hydrochloride 100 mg (Apotex) | |
| Capsules; Oral; Minocycline Hydrochloride 50 mg (Apotex) | |
| Apo-Minocycline cap 100 mg 100's (Apotex) | |
| Apo-Minocycline cap 50 mg 100's (Apotex) | |
| Apominolin (Israel) | |
| Arestin Microspheres | |
| Powder, Extended Release; Subgingival; Minocycline Hydrochloride 1 mg / 4 mg | |
| Arestin Microspheres powder / extended release 1 mg (Orapharma Inc (Canada)) | |
| ARNOCIN | |
| ARNOCIN 100MG CAPSULE 1 strip / 6 capsules each (Dr. Johns Laboratories Pvt Ltd) | $ 3.08 |
| ARNOCIN 100MG TABLET 1 strip / 10 tablets each (Dr. Johns Laboratories Pvt Ltd) | $ 5.14 |
| Arnocin 100mg Tablet (Dr. Johns Laboratories Pvt Ltd) | $ 0.51 |
| Asolmicina (Argentina) | |
| Bagomicina (Chile, Ecuador, Peru) | |
| Tablet, Film-Coated; Oral; Minocycline 100 mg (Bago) | |
| Tablet, Film-Coated; Oral; Minocycline 50 mg (Bago) | |
| Tablets, Film-Coated; Oral; Minocycline 100 mg (Bago) | |
| Tablets, Film-Coated; Oral; Minocycline 50 mg (Bago) | |
| Banimed (Mexico) | |
| Blemix (United Kingdom) | |
| Borymycin (Malaysia, Singapore, Taiwan) | |
| Borymycin 100 mg x 10 x 10's (Ysp) | |
| Borymycin 100 mg x 1000's (Ysp) | |
| Borymycin 50 mg x 10 x 10's (Ysp) | |
| Borymycin 50 mg x 1000's (Ysp) | |
| Borymycin 20 mg/1 g x 1 g (Ysp) | |
| Borymycin 20 mg/1 g x 1 kg (Ysp) | |
| Borymycin 50 mg x 10's x 10 (Ysp) | |
See 642 substitutes for Aknefug Mino | |
References
- PubChem. "minocycline". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "minocycline". http://www.drugbank.ca/drugs/DB01017 (accessed September 17, 2018).
- MeSH. "Anti-Bacterial Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Aknefug Mino are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Aknefug Mino. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
